

PERFORMANCE IN DELIVERING CLINICAL RESEARCH (Q1, 2015/16)

Research Ethics Committee Reference Number	Name of Trial	Target number of patients	Date agreed to recruit target number of patients	Trial status	Target met within the agreed time?	Comments
04/MRE07/35	Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy	69	31/12/2020	Open	N/A	Date agreed to recruit to target not yet passed.
07/H1102/84	Sunitinib treatment of renal adjuvant cancer (S-TRAC) A randomised double blind phase 3 study of adjuvant vs placebo in subjects at high risk of recurrent RCC. Study Number: A6181109	3		Closed - In Follow Up	N/A	Study delivered to target. Study has been in follow up since 2008.
07/Q1206/53	Clinical Trial Protocol CAMN107A2303 - A phase III multi-center, open-label, randomized study of imatinib versus nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CM)	5	15/06/2008	Closed - In Follow Up	Y	Study delivered to time and target.
08/H1010/66	Protocol H3E-MC-JMIG - Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other than Predominantly Squamous Cell Histology	5	01/01/2011	Closed - Follow Up Complete	N	Study reached target by May 2011 (4 months delay) and eventually recruited 12 patients in total.
08/H1102/75	A double-blind, randomized, multicenter, placebo controlled, parallel-group study comparing the efficacy and safety of 0.5mg FTY720 administered orally once daily versus placebo in patients with primary progressive multiple sclerosis	10	01/12/2011	Closed - Follow Up Complete	Y	Study delivered to time and target.
09/H0405/51	A Phase II Study of Dasatinib therapy in children & adolescents with PH+ leukaemia with resistance or intolerance to Imatinib.			Closed - In Follow Up	N/A	No target or date agreed with sponsor.
09/H0711/8	CompERA-XL: Comparison of endothelin receptor antagonist therapy in routine care	200		Open	N/A	No date agreed with sponsor. Study has recruited 92/200 patients.
10/H0406/27	Randomised, Multicentre, Open-label, Phase III Study of Plitidepsin in Combination with Dexamethasone vs. Dexamethasone Alone in Patients with Relapsed/Refractory Multiple Myeloma	6		Closed - In Follow Up	N/A	No date agreed with sponsor.
10/H0605/58	Sub Study to study WN25203, using positron emission tomography (PET) with an amyloid tracer to assess changes in amyloid load over time in subjects with Prodromal Alzheimer's Disease	1	30/09/2012	Closed - In Follow Up	Y	Study delivered to time and target.
10/H0605/59	Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease (WN25203)	6	01/09/2013	Closed - In Follow Up	Y	Study delivered to time and target.
10/H0713/35	An International, multi-center, randomized, controlled trial evaluating the effect of xenon on post-operative delirium in elderly patients undergoing hip fracture surgery	6	31/10/2014	Closed - In Follow Up	Y	Study delivered to time and target.
10/H0715/57	A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy	5	01/11/2011	Closed - In Follow Up	Y	Study delivered to time and target.
10/H0717/68	A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212/Inactivated Varicella-Zoster Virus (VZV) Vaccine in Recipients of Autologous Hematopoietic	3	25/04/2013	Closed - In Follow Up	Y	Study delivered to time and target.
10/H0801/67	Focal MR-Guided Focused Ultrasound Treatment of Localized Low-Risk Prostate Cancer: Feasibility Study	15	17/07/2016	Open	N/A	Date agreed to recruit to target not yet passed.
10/H0904/49	A single arm, open-label, multicenter study evaluating the long-term safety, tolerability and efficacy of 0.5mg fingolimod (FTY720) administered orally once daily in patients with multiple sclerosis	10	01/12/2011	Closed - In Follow Up	Y	Study delivered to time and target.
11/EE/0256	Multi-centre, open label, prospective, consecutive series registry database of BioPoly RS Partial Resurfacing Knee implant	10	31/12/2015	Open	N/A	Date agreed to recruit to target not yet passed.

11/EM/0074	A 2-Year, multicenter, double-masked, randomised, parallel study of the safety of LUMIGAN 0.1 mg/mL compared with LUMIGAN 0.3 mg/mL in patients with glaucoma or ocular hypertension	15	30/09/2014	Closed - In Follow Up	Y	Study delivered to time and target.
11/LO/0449	A multicenter, global, randomized, double-blind study of axitinib versus placebo in patients with advanced hepatocellular carcinoma following failure of one prior antiangiogenic therapy	2	30/06/2012	Closed - In Follow Up	Y	Study delivered to time and target.
11/LO/0537	A Multicenter, randomized, double-blind, placebo-controlled Study of the Efficacy of Natalizumab or Reducing Disability Progression in Subjects with Secondary Progressive Multiple Sclerosis	20	29/03/2013	Closed - In Follow Up	Y	Study delivered to time and target.
11/LO/0551	A phase I Open-Label Dose Escalation Study of the Focal Adhesion Kinase Inhibitor, GSK2256098, in Subjects with Solid tumors	10	31/12/2015	Open	N/A	Date agreed to recruit to target not yet passed.
11/LO/1040	A long-term monitoring study to evaluate the persistence of direct acting antiviral (DAA) treatment-resistant mutations or the durability of sustained virological response (SVR) in patients treated with DAA-containing regimens for chronic hepatitis C infection (CHC) NV22688	2		Closed - Follow Up Complete	N/A	Study met target and recruited 6 patients.
11/LO/1369	A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy	1	31/08/2014	Closed - In Follow Up	Y	Study delivered to time and target.
11/LO/1739	NV27779 - A phase II randomized, double-blind multicenter active-controlled parallel group study to evaluate the sustained virological response of the HCV polymerase inhibitor pro-drug RO5024048 in combination with Telaprevir and Pegasys/Copegus comp	5	01/09/2013	Closed - Follow Up Complete	Y	Study delivered to time and target.
11/LO/1904	A randomized double-blind multiple-dose placebo-controlled trial to establish the efficacy of QBX258 (combination of VAK694 and QAX576) in asthma that is inadequately controlled with inhaled corticosteroids and long acting beta agonists	6	31/05/2013	Closed - Follow Up Complete	Y	Study delivered to time and target.
11/NW/0298	A multicenter, phase III, open-label, randomized study in previously untreated patients with advanced indolent non Hodgkins Lymphoma comparing GA101 (RO5072759) plus chemotherapy with rituximab plus chemotherapy followed by GA101 or rituximab mainten	2	20/12/2013	Closed - In Follow Up	Y	Study delivered to time and target.
11/SC/0454	A phase IIb parallel group, open label study of pegylated interferon alfa-2a monotherapy (PEG-IFN, RO 25-8310) compared to untreated control in children with HBeAg positive chronic hepatitis B	2	01/11/2014	Closed - In Follow Up	Y	Study delivered to time and target.
11/WS/0039	A Phase I/IIa trial of AZD4547 in combination with Cisplatin and Capecitabine (CX)	1	31/03/2015	Closed - Follow Up Complete	Y	Study delivered to time and target.
12/EE/0176	Randomised, phase IV, placebo-controlled, comparative study to evaluate the efficacy and safety of tapering methotrexate (MTX) dosage versus maintaining the dosage in patients with severe active rheumatoid arthritis (RA) who have demonstrated an inad	5	01/01/2014	Closed - Follow Up Complete	N	There were 2 patients recruited. Study had issues with staff availability particularly as it ran across 3 study sites.
12/LO/0098	A randomized, doubleblind, placebo controlled, multiple dose study to evaluate the safety, tolerability, and efficacy of intravenous administration of secukinumab (AIN457) in patients with asthma not adequately controlled with inhaled corticosteroids	6	01/08/2013	Closed - Follow Up Complete	Y	Study delivered to time and target.
12/LO/0858	An OpenLabel Study to Evaluate the Safety, Antiviral Activity and Pharmacokinetics of Direct Acting Antiviral Agent (DAA) Treatment in Combination with Peginterferon a2a and Ribavirin (pegIFN/RBV) in Chronic Hepatitis C Virus (HCV) Infected Subjects			Closed - Follow Up Complete	N/A	This study is a treatment roll-over study so there are no recruitment targets as patients will enter depending on their treatment results in feeder study.
12/LO/1173	An Open Label Phase I/II Study of GSK2110183 in Combination with Carboplatin and Paclitaxel in Subjects with PlatinumResistant Ovarian Cancer	10	31/08/2014	Closed - Follow Up Complete	Y	Study delivered to time and target.
12/LO/1320	Aneurysm Treatment using the HeliFX Aortic Securement System Global Registry	5	26/11/2013	Open	N	Target of 5 patients reached within 14 months; contract stated 12 months.
12/LO/1343	A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating CNTO 3157 in Healthy Normal and Asthmatic Subjects Inoculated with Human Rhinovirus Type 16	2	09/09/2014	Closed - Follow Up Complete	Y	Study delivered to time and target.

12/LO/1597	A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 co-administered with Ribavirin (RBV) in treatment ?experienced adults with genotype 1 chronic hepat	5	01/04/2013	Closed - Follow Up Complete	Y	Study delivered to time and target.
12/LO/1598	A randomized, open label study to evaluate the safety and efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 (coadministered with Ribavirin (RBV) in adults with genotype 1 chronic hepatitis C virus (HCV) infection and cirrhosis (T	4	31/03/2013	Closed - Follow Up Complete	Y	Study delivered to time and target.
12/LO/1698	Valacyclovir in Delaying Antiretroviral Treatment Entry (VALIDATE) Short	10	31/12/2014	Closed - In Follow Up	N	Recruitment has been difficult worldwide - only managed to recruit 192/480 globally. Several other sites have also not reached their target. Study team has spoken to many possible participants but they have declined to take part.
12/LO/1762	Left ventricular MultiSpot Pacing for CRT (i-Spot)	8	24/12/2015	Closed - Follow Up Complete	N	
12/LO/1823	A Randomized, Double-blind Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV 1 Infecte	10	19/12/2013	Closed - In Follow Up	N	2 patients recruited.
12/LO/1861	A Randomised, Open-label, Active-controlled, Multi-centre Study to Evaluate the Safety of Rivaroxaban and Vitamin K Antagonists in Subjects Undergoing Catheter Ablation for Atrial Fibrillation	8	30/06/2014	Closed - Follow Up Complete	Y	Study delivered to time and target.
12/LO/1889	Openlabel,single arm extension study to the doubleblind,randomized, multicenter, placebo controlled,parallel group study comparing the efficacy and safety of 0.5 mg FTY720 administered orally once daily versus placebo in patients with primary progres	6	31/08/2014	Closed - Follow Up Complete	Y	Study delivered to time and target.
12/LO/1966	A Phase 3, Randomized, Placebocontrolled, Parallelgroup, Multicenter, Doubleblind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome Refractory to Somatostatin Analog (SSA) Therapy	1	31/12/2014	Closed - In Follow Up	Y	Study delivered to time and target.
12/LO/1981	A Randomized, Multicenter, Open-Label Phase III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine Versus Trastuzumab As Adjuvant Therapy For Patients With Her2-Positive Primary Breast Cancer Who Have Residual Tumor Present Pathologic	3	01/03/2016	Open	Y	Study delivered to time and target.
12/NW/0137	A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung origin	5	03/11/2017	Closed - In Follow Up	Y	Study delivered to time and target.
12/NW/0251	A multicentre, stratified, open, randomized, comparator-controlled, parallelgroup phase III study comparing treatment with 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in patients with inoperable, progressive, somatostatin receptor positive, midgut	3	01/06/2015	Closed - Follow Up Complete	Y	Study delivered to time and target.
12/NW/0711	Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Month Trial of Leuco-methylthionium bis(hydromethanesulfonate) in Subjects with Mild to Moderate Alzheimer's Disease (TRx-237-015)	10	01/01/2014	Closed - Follow Up Complete	Y	Study delivered to time and target.
12/SC/0538	A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of Leuco-methylthionium bis(hydromethanesulfonate) in Subjects with Behavioral Variant Frontotemporal Dementia (bvFTD)	6	01/01/2014	Closed - In Follow Up	N	7 patients recruited to date.
12/SS/0007	A randomised Phase 2 Placebo-Controlled Study of LY2495655 in Patients with Advanced or Metastatic Pancreatic Cancer Receiving Chemotherapy	4	30/01/2014	Closed - In Follow Up	N	Rare disease study. There were 2 patients recruited.

12/SW/0378	Effect of Bivalirudin on Aortic Valve Intervention Outcomes 2/3 (BRAVO 2/3)	6	02/02/2015	Open	N	Bereavement in study team and after discussion with the study sponsors , we therefore agreed to postpone start of recruitment. First patient was consented in Septemebr 2014.
12/WM/0341	A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular events When AMG 145 is Used in Combination With StatinTherapy in Patients with Clinically Evident C	55	30/11/2014	Closed - Follow Up Complete	N	41 patients recruited to date.
12/WM/0373	A randomised trial in new hearing aid users to measure the benefit of using 4 pre-set configurations of hearing aids with self learning characteristics	50	01/11/2015	Open	Y	Study delivered to time and target.
12/WS/0184	Multi-Center, Open-Label, Randomized Study of Anti-CCR4 Monoclonal AntibodyKW-0761 or Investigators Choice in Subjects with Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)	3	30/06/2014	Open	Y	Study delivered to time and target.
12/YH/0318	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia	5	02/07/2014	Closed - Follow Up Complete	Y	Study delivered to time and target.
12/YH/0504	Assessment of the efficacy and safety of a new wound dressing in the local treatment of diabetic foot ulcers: A Prospective, randomised, controlled, doubleblind, European multicentre clinical trial.	4	29/11/2016	Open	N/A	Date agreed to recruit to target not yet passed.
13/EE/0199	An Exploratory Study of the Safety and Efficacy of BOTOX for the Treatment of Premature Ejaculation	10	01/08/2015	Open	N/A	Date agreed to recruit to target not yet passed.
13/EE/0214	A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects with Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial	1	30/09/2018	Open	Y	Study delivered to time and target.
13/EE/0257	A Phase II Clinical Trial to Study the Efficacy and Safety of a combination regimen of MK-5172 and MK-8742 with Ribavirin (RBV) in Subjects with Chronic Hepatitis C Genotype 2 Infection	1	28/02/2014	Closed - Follow Up Complete	Y	Study delivered to time and target.
13/EE/0364	A Randomized, Doubleblind, Multicenter Phase 2 Trial of Denosumab in Combination with Chemotherapy as Firstline Treatment of Metastatic Nonsmall Cell Lung Cancer.	12	31/05/2015	Closed - In Follow Up	Y	Study delivered to time and target.
13/EE/0429	A phase I/II open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in subjects with relapsed, refractory hematologic malignancies.	6		Open	N/A	No date agreed with sponsor.
13/EE/0444	Maximizing CRT Delivery by using Multipolar Coronary Sinus Lead Acuity x4	20	31/12/2014	Open	N	5 patients recruited into the study. Team continues to try to identify new patients.
13/EM/0348	Safety and Efficacy assessment of Monoprost? (unpreserved latanoprost) in comparison with Lumigan? 0.01 % and Lumigan? 0.03% UD, in patients with primary open angle glaucoma or ocular hypertension, stabilized by Lumigan? 0.01 % with ocular surfac	6	31/08/2015	Closed - In Follow Up	Y	Study delivered to time and target.
13/EM/0374	A doubleblind, randomized, placebocontrolled, study to demonstrate the efficacy and safety of 250 mg or 1 g A3384 administered orally twice daily for two weeks to patients with Bile Acid Malabsorption (BAM)/Bile Acid Diarrhoea (BAD)			Closed - Follow Up Complete	N/A	No target or date agreed with sponsor. There have been 12 patients recruited. Although team was consenting and screening early on, there was a high dropout rate delaying the date of first patient recruited.

13/EM/0460	A RANDOMIZED, MULTICENTER, OPEN-LABEL TRIAL COMPARING CHEMOTHERAPY PLUS TRASTUZUMAB PLUS PERTUZUMAB VERSUS CHEMOTHERAPY PLUS TRASTUZUMAB EMTANSINE PLUS PERTUZUMAB AS ADJUVANT THERAPY IN PATIENTS WITH OPERABLE HER2 POSITIVE PRIMARY BREAST CANCER	6	28/02/2016	Closed - In Follow Up	N	Study closed to recruitment early (nationally) by the Sponsor (closed 22/05/2015) which is why we did not recruit to time and target. This was due to newly available data from the phase III MARIANNE study.
13/LO/0129	A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects	6	31/05/2014	Closed - Follow Up Complete	N	Several months delay in Sponsor conducting site initiation - impacted on site's ability to recruit in tht period. Total of 3 patients recruited.
13/LO/0150	A randomized, double blind, placebo-controlled, multicenter phase III study of regorafenib in patients with hepatocellular carcinoma (HCC) after sorafenib	4	23/11/2016	Open	N/A	Date agreed to recruit to target not yet passed.
13/LO/0326	A RANDOMIZED, PHASE 3 STUDY OF GANETESPIB IN COMBINATION WITH DOCETAXEL VERSUS DOCETAXEL ALONE IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG ADENOCARCINOMA	2	30/09/2016	Open	N/A	Date agreed to recruit to target not yet passed.
13/LO/0425	A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and BT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults with Genotype 1a Chronic Hepatit	5	01/05/2013	Closed - Follow Up Complete	N	Study had very tight UK set-up timelines; it was already almost fully recruited in the US when UK sites were opened. UK sites only had 4 days to recruit (6-May to 10-May-13). Follow up ended on 27/08/2014.
13/LO/0501	A PHASE 2, RANDOMIZED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND ANTI-CYTOMEGALOVIRUS (CMV) ACTIVITY OF MARIBAVIR VERSUS VALGANCICLOVIR FOR TREATMENT OF CMV INFECTIONS IN TRANSPLANT RECIPIENTS WHO DO NOT HAVE CMV ORGAN DISEASE	1	31/03/2014	Closed - Follow Up Complete	N	Sponsor required extensive protocol-specific training in various electronic systems, which delayed set-up of the study here because of the large number of people involved that would need to undertake this training. Recruitment was closed by Sponsor before our site had a chance to enrol a patient.
13/LO/0535	A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis	3	26/06/2014	Closed - In Follow Up	Y	Study delivered to time and target.
13/LO/0615	A Randomized, Controlled, Open-Label, Phase 2, Trial of SGI-110 and Carboplatin in Subjects with Platinum-Resistant Recurrent Ovarian Cancer	5	01/05/2014	Closed - Follow Up Complete	Y	Study delivered to time and target.
13/LO/0671	A Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Study 205MS301	7	28/02/2014	Closed - In Follow Up	Y	Study delivered to time and target.
13/LO/0855	A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Rituximab for Previously Treated Indolent Non-Hodgkin Lymphoma	4		Open	N/A	No date agreed with sponsor.
13/LO/1050	A Multicenter, Randomized, OpenLabel, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in FirstLine Treatment of Subjects With Unresectable Hepatocellular Carcinoma	5		Open	N/A	No date agreed with sponsor.
13/LO/1081	A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer	1	31/12/2018	Open	Y	Study delivered to time and target.
13/LO/1121	A Randomized, Controlled Phase 2 Study Evaluating LY2875358 plus Erlotinib versus Erlotinib as First Line Treatment in Metastatic Non Small Cell Lung Cancer Patients with Activating EGFR Mutations Who Have Disease Control after an 8 Week Lead In Tre	4	01/03/2015	Closed - In Follow Up	Y	Study delivered to time and target.
13/LO/1227	A Multicenter, Randomized, DoubleBlind, PlaceboControlled, Phase III Study of ARN509 in Men with NonMetastatic (M0) CastrationResistant Prostate Cancer	5	30/11/2018	Open	N/A	Date agreed to recruit to target not yet passed.

13/LO/1302	A Phase IIIb randomised, openlabel study of the safety and efficacy of dolutegravir/abacavir/lamivudine once daily compared to atazanavir and ritonavir plus tenofovir/emtricitabine once daily in HIV1 infected antiretroviral therapy naive women.	4	01/08/2014	Closed - In Follow Up	Y	Study delivered to time and target.
13/LO/1323	The efficacy and safety of Ferriprox for the treatment of transfusional iron overload in patients with sickle cell disease or other anaemias	5	31/12/2014	Open	N	Study team has confirmed that of the 5 patients seen across the Trust during the recruitment period, 2 failed screening. This resulted in the target number (5) being missed. In addition, due to the significant SIV and IMP delivery delay, the time to recruit had been reduced.
13/LO/1332	A TwoPart Phase 1/2a, OpenLabel, Dose Escalation Study to Evaluate the Tolerability and Preliminary Antitumour Activity of OPB111001 in Patients with Advanced Cancers that are Poorly Responsive to Standard Anticancer Treatment	30		Suspended	N/A	No date agreed with sponsor.
13/LO/1352	A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) COMPARED WITH DOCETAXEL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AFTER PLATINUM FAILURE	2	31/03/2014	Closed - In Follow Up	Y	Study delivered to time and target.
13/LO/1557	A Phase IV, Multicentre, Open label, Single Group Exploratory Study to Assess the Clinical Value of Enumeration of Circulating Tumour Cells (CTCs) to Predict Clinical Symptomatic Response and Progression Free Survival in Patients receiving Deep Subcu	5	31/08/2016	Open	N/A	Date agreed to recruit to target not yet passed.
13/LO/1682	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients with Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian,	5	31/12/2016	Open	N/A	Date agreed to recruit to target not yet passed.
13/LO/1758	A Phase III, Randomized, PlaceboControlled, ParallelGroup, DoubleBlind Clinical Trial to Study the Efficacy and Safety of MK8931 (SCH 900931) in Subjects with Amnesic Mild Cognitive Impairment Due to Alzheimer?s Disease (Prodromal AD).	10		Open	N/A	No target or date agreed with sponsor. 6 patients recruited to date
13/LO/1814	A phase III, randomized, controlled, single-blind, multicentre, parallel arm trial to assess the efficacy and safety of Pergoveris? (follitropin alfa and lutropin alfa) and GONAL-f? (follitropin alfa)			Closed - In Follow Up	N/A	No target/date agreed with sponsor.
13/NE/0125	PRESTO Neo.1.C/E	8	01/08/2014	Withdrawn	N	Screened large numbers of patients comparable with other sites but have been unable to recruit. The intervention timing is challenging for new mothers who are breast feeding. The sponsor has acknowledged these challenges across all open sites. Study was eventually withdrawn.
13/NE/0126	An exploratory, randomised, doubleblind, controlled study to assess the effect of an Amino Acid Based Formula with a synbiotic blend on gut microbiota and stool in infants with suspected gastrointestinal Non IgE mediated cow's milk allergy - ASSIGN NEO.1.C/F	4	31/10/2014	Closed - Follow Up Complete	N	Inclusion criteria was an obstacle as the cut off is 13 months of age. The age of referred children is older and they are therefore excluded.

13/NE/0177	A phase II, randomised, double-blind, placebo-controlled study to evaluate LUM001, an apical sodium-dependent bile acid transporter inhibitor (ASBTI), in combination with ursodeoxycholic acid (UDCA) in patients with primary biliary cirrhosis	3	01/03/2014	Closed - Follow Up Complete	N	Rare disease study.
13/NI/0160	Management of myocardial injury After NonCardiac surgGery (MANAGE)	20	18/12/2015	Open	N/A	Date agreed to recruit to target not yet passed.
13/NI/0188	A singlearm trial to evaluate the effectiveness of PCI of de novo vessel disease applying the SYNTAX score II with pressure wire functional assessment and IVUS guidance, using an everolimuseluting stent with biodegradable abluminal coating	17	31/12/2019	Open	Y	Study delivered to time and target.
13/NW/0002	Prospective, randomised, controlled investigation comparing the safety and performance of 032-11 Surgical Haemostat 2g Applicator with FLOSEAL Hemostatic Matrix as an adjunctive haemostat in cardiac surgery and thoracic aortic surgery -VICTORY Study	20	31/07/2015	Open	N/A	Date agreed to recruit to target not yet passed.
13/NW/0363	A Multicenter Openlabel Extension (OLE) Study to Assess the Long term Safety and Efficacy of AMG 145	8	01/01/2014	Closed - Follow Up Complete	N	2 patients recruited.
13/NW/0464	A PlaceboControlled, Multicenter, DoubleBlind, Randomized, Pharmacokinetic and Pharmacodynamic Trial of IDN6556 in Subjects with Acute on Chronic Liver Failure	4	31/03/2014	Closed - Follow Up Complete	N	Inclusion/exclusion was too restrictive in the original protocol. Substantial Amendments submitted in order to broaden the potential patient population. The population is of very sick patients who are inpatients and normally on ITU. Some will not have the capacity to consent. The sponsor withdrew the option of having a consultee consent on behalf of patients. Other UK sites have had problems recruiting to this study as well.
13/NW/0583	A 24-Week International, Multi-center, Randomized, Parallel-group, Double-blind Trial to Evaluate Metformin Extended Release Monotherapy Compared to Metformin Immediate Release Monotherapy in Adult Subjects with Type 2 Diabetes who have Inadequate GI			Open	N/A	No target or date agreed with sponsor.
13/NW/0634	A Phase 1b, multicenter, openlabel, dose escalation study of GSK2256098 (FAK inhibitor) in combination with Trametinib (MEK inhibitor) in subjects with advanced solid tumors	5	30/06/2016	Open	N/A	Date agreed to recruit to target not yet passed.
13/NW/0697	PiSARRO: p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246	4	14/02/2016	Open	Y	Study delivered to time and target.
13/NW/0778	A double-blind, randomised, placebo-controlled, Phase II study to evaluate ProCervix efficacy to clear HPV 16 and HPV 18 infection in women with normal cytology or ASCUS/LSIL	1	30/11/2014	Closed - In Follow Up	Y	Study delivered to time and target.
13/SC/0092	A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312)in patients with secondary progressive multiple sclerosis (Protocol No: CBAF312A230	6	30/04/2014	Closed - In Follow Up	N	Sponsor delays with IMP supply. There are 5 patients recruited.
13/SC/0259	A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas. Gilead GS-US-313-0125	3	31/10/2014	Closed - In Follow Up	Y	Study delivered to time and target.

13/SC/0311	A randomized, controlled, doubleblind Phase III trial to compare the efficacy, safety and pharmacokinetics of GP2013 plus cyclophosphamide, vincristine, prednisone vs. MabThera? plus cyclophosphamide, vincristine, prednisone, followed by GP2013 o	3	31/12/2014	Closed - In Follow Up	N	Study recruited one subject. Sadly there were not as many eligible patients as we expected during the relatively short recruitment window (the study recruited much faster than anticipated and closed sooner).
13/SC/0348	A randomized, OpenLabel, Phase 2 Study Evaluating LY2875358 Plus Erlotinib and LY2875358 Monotherapy in MET Diagnostic Positive NSCLC Patients with Acquired Resistance to Erlotinib	3	01/10/2014	Closed - Follow Up Complete	Y	Study delivered to time and target.
13/SC/0360	A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa 2a and Ribavirin, Each Administered with Telaprevir in Subjects with Genotype-1 Chronic Hepatitis C who are Treatment-Naive or Relapsed on Trea	4	21/10/2013	Closed - Follow Up Complete	Y	Study delivered to time and target.
13/SC/0383	A Two Part, Randomized Clinical Trial to Study Biomarkers of MK8237 (SCH 900237) Treatment in Subjects with House Dust Mite Induced Allergic Rhinitis or Rhinoconjunctivitis	20	31/01/2015	Closed - In Follow Up	Y	Study delivered to time and target.
13/SC/0559	A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome	2	31/03/2015	Closed - In Follow Up	N	This is a rare disease study with very few suitable patients; also several patients declined to take part.
13/SC/0589	Optimisation of Onpulse technology for patients with post surgical or vascular oedema	10	30/07/2014	Closed - Follow Up Complete	N	Study completed target in November 2014.
13/SW/0124	A PERFORMANCE EVALUATION STUDY OF UROSENS? MCM5-ELISA FOR THE DETECTION OF PROSTATE CANCER IN PATIENTS WITH KNOWN DISEASE AND IN THOSE PRESENTING WITH RAISED SERUM PROSTATE-SPECIFIC ANTIGEN AND/OR ABNORMAL PROSTATE GLAND MORPHOLOGY	19	28/02/2014	Closed - In Follow Up	Y	Study delivered to time and target.
13/WA/0064	A performance evaluation study of UROSENS MCM5 ELISA test in the diagnosis of bladder cancer in patients presenting with haematuria and lower urinary tract symptoms with suspicion of malignancy	250	15/01/2014	Closed - In Follow Up	N	Target of 250 patients reached within 10 months; contract stated 8 months.
13/WA/0328	Randomized controlled study comparing AEZS-108 with doxorubicin as second line therapy for locally advanced, recurrent or metastatic endometrial cancer	2	31/07/2015	Open	Y	Study delivered to time and target.
13/WS/0172	A Phase 2, Open-Label Study of Rucaparib in Patients with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	8	13/12/2015	Suspended	N	Recruitment was suspended on 31st October 2014. Site only activated at the end of August 2014 and we did not manage to recruit any patients before the recruitment was suspended, mainly because there were no eligible patients seen in the 2 month period.
13/WS/0282	Prospective, single-arm, global multi-center study to evaluate treatment of obstructive superficial femoral artery and/or popliteal lesions with a novel paclitaxel coated percutaneous angioplasty balloon.	10	01/01/2016	Closed - In Follow Up	Y	Study delivered to time and target.
13/YH/0275	Revitive for the treatment of venous insufficiency	20	01/07/2014	Closed - Follow Up Complete	N	
13/YH/0317	Current Steering to Optimize Deep Brain Stimulation	4	30/11/2014	Closed - Follow Up Complete	Y	Study delivered to time and target.
14/EM/0130	A Phase 3, Open-Label, Randomized Study of Quizartinib (AC220) Monotherapy vs. Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory to, or Relapsed after, First-Line Treatment	2	30/06/2016	Open	N/A	Rare disease study. Date agreed to recruit to target not yet passed.
14/EM/0186	A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis	2	14/08/2018	Open	N/A	Date agreed to recruit to target not yet passed.

14/EM/1059	A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura	1	14/11/2015	Open	N/A	Date agreed to recruit to target not yet passed.
14/EM/1060	A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura	1	14/11/2015	Open	N/A	Date agreed to recruit to target not yet passed.
14/LO/0102	A First Time in Human, Double Blind, Randomised, Placebo Controlled Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Intravenous Doses of SNF472 in Healthy Male Volunteers	8		Open	N/A	No date agreed with sponsor. Study has recruited 3/8 patients.
14/LO/0362	Prospective, randomized, placebo-controlled, double-blind, multicenter, parallel-group, 24-week study to assess the efficacy, safety and tolerability of macitentan in subjects with inoperable chronic thromboembolic pulmonary hypertension	3	28/08/2015	Open	N/A	Date agreed to recruit to target not yet passed.
14/LO/0521	A prospective, randomized, open label, two arm Phase III study to evaluate treatment free remission (TFR) rate in patients with Philadelphia positive CML after two different durations of consolidation treatment with nilotinib 300mg BID.	1	01/12/2019	Closed - In Follow Up	Y	Study delivered to time and target.
14/LO/0665	A Phase III OpenLabel Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK5172/ MK8742 in TreatmentNa?ve Subjects with Chronic HCV GT1, GT4, GT5, and GT6 Infection who are on Opiate Substitution Therapy.	4		Closed - Follow Up Complete	N/A	Study delivered to target.
14/LO/0673	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS 1101 (CAL-101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia.	7	31/03/2018	Open	N/A	Date agreed to recruit to target not yet passed.
14/LO/0717	A Multicenter Phase 3 Randomized Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukaemia.	2	12/05/2020	Open	Y	Study delivered to time and target.
14/LO/0865	A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy	5		Open	N/A	No date agreed with sponsor.
14/LO/0882	A PHASE III, OPEN-LABEL, MULTICENTER,RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) COMPARED WITH DOCETAXEL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY	4	01/06/2015	Closed - In Follow Up	Y	Study delivered to time and target.
14/LO/1053	A Phase 3 Randomised double blind Active study Evaluating Memelotinib vs Ruxolitinib in subjects with primary Myelofibrosis (PMF) or Post-poly cythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)	2	01/12/2017	Open	N/A	Date agreed to recruit to target not yet passed.
14/LO/1381	A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Reformulated Raltegravir 1200 mg Once Daily versus Raltegravir 400 mg Twice Daily, Each in Combination with TRUVADA	5	30/04/2015	Closed - In Follow Up	N	Study closed to recruitment by sponsor before agreed date to recruit by.
14/LO/1728	A Phase Ib Open Label Study of the Safety and Tolerability of ME-344 Given in Combination with Topotecan (Hycamtin?) in Patients with Solid Tumors	2	28/02/2017	Open	Y	Study delivered to time and target.
14/LO/1834	A Phase I randomised, placebo-controlled, double-blind, single and multiple ascending dose study of the tolerability and pharmacokinetics of GBT440 in healthy subjects and patients with Sickle Cell Disease	2	24/07/2015	Open	Y	Study delivered to time and target.
14/LO/1994	The AMARANTH study - A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled,Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer?s Disease			Open	N/A	Study recently open and recruitment has not yet started.
14/LO/2143	Measurement of low-energy stimulation in patients with atrial fibrillation	15	15/12/2015	Open	N/A	Date agreed to recruit to target not yet passed.
14/LO/2196	A phase 2, double-blind, parallel group, randomised, placebo controlled, proof of concept study to assess the safety and efficacy of OBE001 after oral administration in pregnant women with threatened preterm labour	7		Open	N/A	

14/NE/1072	A PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED BRONCHOSCOPY STUDY TO EVALUATE THE EFFECTS OF LEBRIKIZUMAB ON AIRWAY EOSINOPHILIC INFLAMMATION IN PATIENTS WITH UNCONTROLLED ASTHMA ON INHALED CORTICOSTEROIDS AND A SECOND CONTROLLER MEDICATION			Open	N/A	Inclusion/exclusion criteria for study is very narrow and no patients have been recruited to date despite actively screening. Sponsor is aware of difficulties and a meeting between site and sponsor is to take place to discuss restrictive inclusion criteria.
14/NW/0008	Golimumab: A Phase 4, UK Open Label, Single arm Study on its Utilization and Impact in Ulcerative Colitis	6	31/03/2016	Closed - In Follow Up	N	Study closed to recruitment by sponsor before agreed date to recruit by.
14/NW/0036	ESPAC 5 - Four arm, prospective, multicentre, randomised feasibility trial of immediate surgery compared with neoadjuvant chemotherapies and neoadjuvant chemoradiotherapy	5	31/10/2017	Open	N/A	Date agreed to recruit to target not yet passed.
14/NW/0130	A randomised, double blind, multi-center, placebo-controlled study to evaluate the efficacy, safety, and tolerability of NT100 in pregnant women with a history of unexplained recurrent pregnancy loss (RPL)	20	01/06/2015	Open	Y	Study delivered to time and target.
14/NW/0156	OlympiAD - Olaparib monotherapy V Physicians choice chemotherapy	1	31/10/2015	Open	N/A	Date agreed to recruit to target not yet passed.
14/NW/0290	Registry of Deep Brain Stimulation with the VERCISE? System: Vercise DBS Registry	10		Open	N/A	No date agreed with sponsor.
14/NW/1354	Romiplostim in Thrombocytopenic Paediatric Patients with ITP	5	28/02/2017	Open	N/A	Date agreed to recruit to target not yet passed.
14/NW/1427	A Phase 3, Randomized Study Investigating the Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinsons Disease Patients With Motor Response Fluctuations (OFF Phenomena) Compared to an Observational Cohort Control	4	13/12/2017	Open	N/A	Date agreed to recruit to target not yet passed.
14/SC/0037	A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, EFFICIACY AND SAFETY STUDY OF GANTENERUMAB IN SUBJECTS WITH MILD ALZHEIMER'S DISEASE	6	31/01/2016	Open	N/A	Date agreed to recruit to target not yet passed.
14/SC/0038	PET IMAGING SUBSTUDY ASSOCIATED WITH: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, EFFICIACY, AND SAFETY STUDY OF GANTENERUMAB IN PATIENTS WITH MILD ALZHEIMER'S DISEASE	5	31/01/2016	Open	N/A	Date agreed to recruit to target not yet passed.
14/SC/0132	A phase I, open label study to assess the pharmacokinetic profile, safety and tolerability of OBE001 after a single oral administration in pregnant women with medically indicated pregnancy termination.	6	31/10/2014	Open	N	Study recruits pregnant women who need to have a termination. It requires them to have surgical procedure but many of them do not consent as feel emotionally vulnerable and do not want to have surgery.
14/SC/0178	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Bendamustine and Rituximab for Previously Untreated Chronic Lymphocytic Leukemia	2	31/08/2016	Closed - Follow Up Complete	Y	Study delivered to time and target.
14/SC/0262	A Phase IV, prospective, open-label, uncontrolled, European Study in patients with neovascular Age-related macular degeneration (nAMD), evaluating the efficacy and safety of switching From intravitreal Aflibercept to Ranibizumab 0.5mg: SAFARI study	6	30/10/2016	Open	N/A	Date agreed to recruit to target not yet passed.
14/SC/1014	A Randomized, DoubleBlind, Phase 3 Study of the JAK1/2 Inhibitor, Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas (The JANUS 1 study)	2	26/01/2016	Open	Y	Study delivered to time and target.
14/SW/0091	Randomized, DoubleBlind, Multicenter, Phase 3 Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous NonSmall Cell Lung Cancer (NSCLC)	6	31/03/2016	Open	N/A	Date agreed to recruit to target not yet passed.
14/WM/0170	A Phase 3, Randomized Study To Evaluate the Efficacy of Momelotinib versus Best Available Therapy in Anemic or Thrombocytopenic Subjects with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis,	2	01/10/2020	Open	Y	Study delivered to time and target.

14/WM/1055	A prospective, multicenter, randomized, double blind, placebocontrolled, 2parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with FOLFIRI to placebo in combination with FOLFIRI	5	01/09/2017	Open	N/A	Date agreed to recruit to target not yet passed.
14/WM/1056	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects with Chronic HCV	6		Closed - Follow Up Complete	N/A	Study delivered to time and target. 7 patients recruited; target reached 2 months prior to agreed date.
14/WM/1202	B0401016: A Phase 1b, Randomized, Double-Blind (Sponsor Open), Placebo-Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04447943, (...) In Subjects With Stable Sickle Cell Disease	5		Open	N/A	No date agreed with sponsor.
14/WM/1262	An Open Label Study of Sofosbuvir/GS5816 FixedDose Combination in Subjects with Chronic HCV Infection	1		Open	N/A	Study recruited to target.
14/WS/1105	REVEAL 101MS408 Multicenter study of Natalizumab v Fingolimod in MS	20	25/01/2016	Open	N/A	Date agreed to recruit to target not yet passed.
14/YH/0049	A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of the Combined Lysis of Thrombus with Ultrasound and Systemic Tissue Plasminogen Activator (tPA) for Emergent Revascularization (CLOTBUST-ER) in Acute Ischemic Stroke.	10	31/12/2016	Closed - Follow Up Complete	N	Study recruited 8/10 patients but was closed by sponsor much earlier than expected because of a data review on 26th March 2015 which concluded futility. Site confident they would have easily exceeded target if the study had kept running as expected.
14/YH/0123	An Expanded Access Protocol for Idelalisib (GS-1101) in Combination with Rituximab for Relapsed, Previously Treated Subjects with Chronic Lymphocytic Leukemia.	2	30/04/2016	Closed - Follow Up Complete	Y	Study delivered to time and target.
14/YH/1057	A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks with Sofosbuvir and Ribavirin for 24 Weeks in Subjects with Chronic Genotype 3 HCV Infection	9		Closed - Follow Up Complete	N/A	Study delivered to target. Full target (9) patients recruited in the same month R&D approval was granted.
14/YH/1153	An Open-Label, Extension Study of the Effects of Leuco-methylthionium bi (hydromethanesulfonate) in Subjects with Alzheimer?s Disease or Behavioral Variant Frontotemporal Dementia	10		Open	N/A	Study reached target by April 2015, within 5 months from R&D approval.
14/YH/1234	A phase III, doubleblind, randomised study to assess the efficacy and safety of AZD9291 versus a standard of care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as firstline treatment in patients with (...) NonSmall Cell Lung Cancer	2	28/02/2016	Open	N/A	Date agreed to recruit to target not yet passed.
15/LO/0140	CLEANER Assessment of efficacy and safety for a new wound dressing URGO 310 3166 in the local treatment of venous or mixed leg ulcers: a European, randomised clinical trial.	4	31/08/2016	Open	N/A	Date agreed to recruit to target not yet passed.
15/LO/0210	An exploratory, open-label, multicenter study to evaluate the safety and efficacy of ATIR, donor T-lymphocytes depleted ex vivo of host alloreactive T-cells, in patients with a hematologic malignancy, who received a CD34-selected (...) cell	1	15/07/2017	Open	Y	Study delivered to time and target.
15/WS/0037	A single-arm, post-market study of the Endo GI Reinforced Reload with Tri-Staple Technology	30	01/05/2016	Open	N/A	Date agreed to recruit to target not yet passed.